CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,585,411
- in 7 filings, $4.5M under 10b5-1 plans
Net −$6,585,411. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-25 | Davis Todd C Chief Executive Officer | Option exercise | +2,855 | $67.24 | $192K | 114,448 |
| 2024-03-25 | Davis Todd C Chief Executive Officer | Option exercise | +2,156 | $68.51 | $148K | 116,604 |
| 2024-03-25 | Davis Todd C Chief Executive Officer | Option exercise | +3,556 | $66.19 | $235K | 120,160 |
| 2024-03-25 | Davis Todd C Chief Executive Officer | Option exercise · Non-Qualified Stock Option (right to buy) | −7,448 | 0 | ||
| 2024-03-25 | Davis Todd C Chief Executive Officer | Option exercise · Non-Qualified Stock Option (right to buy) | −3,556 | 0 | ||
| 2024-03-25 | Davis Todd C Chief Executive Officer | Option exercise · Non-Qualified Stock Option (right to buy) | −2,855 | 0 | ||
| 2024-03-25 | Davis Todd C Chief Executive Officer | Option exercise · Non-Qualified Stock Option (right to buy) | −2,156 | 0 | ||
| 2024-03-05 | Sabba Stephen L Director | Option exercise | +2,893 | 30,819 | ||
| 2024-03-05 | Sabba Stephen L Director | Sale | −1,893 | $74.30 | $141K | 28,926 |
| 2024-03-05 | Sabba Stephen L Director | Option exercise · Non-Qualified Stock Option (right to buy) | −2,893 | 419 | ||
| 2024-03-05 | Aryeh Jason Director | Option exercise | +2,893 | $39.35 | $114K | 74,422 |
| 2024-03-05 | Aryeh Jason Director | Option exercise · Non-Qualified Stock Option (right to buy) | −2,893 | 0 | ||
| 2024-02-28 | Espinoza Octavio Chief Financial Officer | Option exercise | +799 | $55.75 | $45K | 29,430 |
| 2024-02-28 | Espinoza Octavio Chief Financial Officer | Option exercise | +140 | $57.22 | $8K | 29,570 |
| 2024-02-28 | Espinoza Octavio Chief Financial Officer | Option exercise | +325 | $58.49 | $19K | 29,895 |
| 2024-02-28 | Espinoza Octavio Chief Financial Officer | Sale | −140 | $88.46 | $12K | 29,755 |
| 2024-02-28 | Espinoza Octavio Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) | −799 | 2,869 | ||
| 2024-02-28 | Espinoza Octavio Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) | −140 | 7,722 | ||
| 2024-02-28 | Espinoza Octavio Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) | −325 | 1,607 | ||
| 2024-02-27 | Reardon Andrew CHIEF LEGAL OFFICER & | Grant or award | +7,208 | 22,205 |
Page 23 of 43 · 858 trades